Skip to main content
. Author manuscript; available in PMC: 2015 May 2.
Published in final edited form as: FEBS Lett. 2014 Apr 12;588(9):1850–1856. doi: 10.1016/j.febslet.2014.03.057

Figure 2. JMJD3 promotes osteogenic differentiation of hMSCs by regulating osteogenic transcription factors.

Figure 2

(A) qRT-PCR of EZH2, JMJD3, and RUNX2 following differentiation of hMSCs treated with either JMJD3 inhibitor GSK-J4 or 0.02% DMSO. The fold change in transcript levels following GSK-J4 treatment is shown relative to vehicle treatment. (B) Promoter regions of SP7, RUNX2, BMP2, and GAPDH were examined by ChIP using either anti-H3K27me3 antibody or anti-IgG control antibody. Enrichment is presented as percent of chromatin input. All graphs exhibit the mean value ± SEM of 3 biological replicates. *P<0.05, **P<0.01, ***P<0.001; statistical differences were calculated by Student’s t test.